PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma with poor outcomes in patients with relapsed/refractory (R/R) disease. PMBL is characterized by high expression of programmed death-1 ligand and variable expression of CD30. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, may have synergistic activity in R/R PMBL. METHODS: The expansion cohort of the open-label, phase I/II CheckMate 436 study enrolled patients with confirmed R/R PMBL who were previously treated with either autologous hematopoietic cell transplantation or two or more prior chemotherapy regimens if ineligible for autologous hematopoietic cell t...
WOS: 000411827200025PubMed ID: 28961828Background: Reed-Sternberg cells of classical Hodgkin's lymph...
BACKGROUND: Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with dif...
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal ...
PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma wi...
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell ly...
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell ly...
Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor res...
open21siFunding agency: Bristol-Myers Squibb United States Department of Health & Human Service...
PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) ha...
PubMedID: 28961828Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are charact...
PURPOSE: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diff...
Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon, but aggressive, type of B-cell lym...
Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has ...
WOS:000368021800236International audienceBACKGROUND: It has been recently shown that nivolumab, a pr...
Background: PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity i...
WOS: 000411827200025PubMed ID: 28961828Background: Reed-Sternberg cells of classical Hodgkin's lymph...
BACKGROUND: Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with dif...
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal ...
PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma wi...
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell ly...
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell ly...
Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor res...
open21siFunding agency: Bristol-Myers Squibb United States Department of Health & Human Service...
PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) ha...
PubMedID: 28961828Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are charact...
PURPOSE: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diff...
Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon, but aggressive, type of B-cell lym...
Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has ...
WOS:000368021800236International audienceBACKGROUND: It has been recently shown that nivolumab, a pr...
Background: PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity i...
WOS: 000411827200025PubMed ID: 28961828Background: Reed-Sternberg cells of classical Hodgkin's lymph...
BACKGROUND: Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with dif...
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal ...